Longer lives, bigger profits: Why I’m bullish on GlaxoSmithKline plc, McCarthy and Stone plc and Carnival plc

Will adding GlaxoSmithKline (LON:GSK), McCarthy and Stone (LON:MCS) and Carnival (LON:CCL) give vitality to your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Life expectancy has grown rapidly over recent decades. This is a good thing for us, of course, and it may also be good for our investments. Today, I’ll be looking at three companies that are likely to benefit most.

In need of a health kick?

People will always need medicine, especially as populations (particularly in developing markets) continue to grow and as developed world citizens live longer. With this in mind, adding a pharmaceutical giant to your portfolio may be a shrewd move.

GlaxoSmithKline (LSE:GSK) seems as good a candidate as any. Shares have disappointed over the last few years, dipping to 1,237p last September as a result of concerns surrounding the loss of profit-generating patents. Things now seem to be on the mend. The forthcoming departure of CEO Sir Andrew Witty and some positive figures in the April’s Q1 earnings release has led analysts to start re-evaluating the company and its future prospects.

Glaxo’s share currently trade at 1,410p. While not screamingly cheap with a P/E ratio of 16, the accompanying 80p per share dividend is a fairly decent sticking plaster for now. Although there have been concerns about Glaxo’s ability to cover this payout, these should abate if the company can prove it’s still on the road to recovery when it announces its Q2 results at the end of July.

Time to build a position?

Shares in retirement homes builder, McCarthy and Stone (LSE:MCS) have dropped rather heavily since their peak of 287p in January, perhaps more as a result of general market jitters and the forthcoming EU referendum than anything to do with the company itself. Indeed, the firm’s first set of half-year results since returning to the market last August certainly gave investors reason for cheer.

Reporting a 33% rise in revenue, Chairman John Wright commented that the group had made “strong progress” towards its goal of building and selling more than 3,000 properties every year. Underlying profit before tax increased by 23% to £39.1m with legal completions up by 19% to 923 units. A 1p interim dividend may sound miserly compared to huge payouts offered by other housebuilders, but this dividend is expected to rise rapidly to 6.78p in 2017, covered over three times by earnings.

Having a 70% share in this niche market gives McCarthy and Stone a dominant position over competitors, something that may become even more apparent as a greater proportion of baby boomers downsize. A 26% jump in the order book from £243m to £306m in one year would appear to back this up.

Calm waters ahead 

The imminent maiden voyage of the gigantic Harmony of the Seas cruise liner has made headlines this week. Cruises have appealed to those in retirement but the fact that people are now far more active in their senior years, and given that it’s the fastest growing sector of the global tourism industry, would suggest companies like Carnival (LSE:CCL) will benefit massively now and in the future.

According to Stockopedia, the £27bn cap has a PEG ratio of 0.89 for the current year. Experienced investors will know that anything under 1 signals they’re getting a lot of growth for their money. A dividend yield of just under 2.5%, while fairly average for a mature FTSE100 company, indicates the board is confident of profits being on a steady course.

Paul Summers owns shares in GlaxoSmithKline and McCarthy and Stone.  The Motley Fool has recommended shares in GlaxoSmithKline.  We fools don’t all hold the same views but we all believe that considering a diverse range of insights makes us better investors.

 

More on Investing Articles

Happy parents playing with little kids riding in box
Investing Articles

Up 12% in a month, Hollywood Bowl is a UK dividend stock on a roll

This 5%-yielding dividend stock was one of the top performers in the FTSE 250 index today. What sent it flying…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

Young investors are taking the stock market on a rollercoaster ride. Here’s how retirees can buckle up

Mark Hartley reveals the volatile impact that younger investors are having on the stock market and how UK retirees can…

Read more »

Two female adult friends walking through the city streets at Christmas. They are talking and smiling as they do some Christmas shopping.
Investing Articles

£7,500 invested in Aviva shares 5 years ago is now worth…

A lump sum pumped into Aviva shares half a decade ago has grown a lot. Andrew Mackie looks at the…

Read more »

Young female hand showing five fingers.
Investing Articles

Could £20,000 invested in these 5 dividend shares produce £14,760 of passive income over the next 10 years?

James Beard considers the potential of dividend shares to deliver amazing levels of passive income. Here are five that have…

Read more »

Workers at Whiting refinery, US
Investing Articles

At 570p, is it too late to consider buying BP shares?

Since the end of February, when the conflict in the Middle East started, BP shares have soared nearly 20%. But…

Read more »

Aviva logo on glass meeting room door
Investing Articles

5 years ago, £5,000 bought 1,231 Aviva shares. But how many would it buy now?

Buying Aviva shares in April 2021 would have been a good decision. And the insurance, wealth, and retirement group’s dividends…

Read more »

Nottingham Giltbrook Exterior
Investing Articles

5 years ago, £5,000 bought 3,185 Marks & Spencer shares. But how many would it buy now?

According to a recent survey, Marks & Spencer is the UK’s best brand. Does this mean it’s time to consider…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is the 8.7% yield on this FTSE 250 stock too good to be true?

FTSE 250 stocks are often overlooked by income investors. Here’s one that’s currently (15 April) yielding over twice that of…

Read more »